CD274 and cancer: Given that CTLA-4 and PD-1/PD-L1 pathways create a mechanism through which cancer cells avoid anti-tumour responses, the blockade of these pathways aimed at reversing T-cell exhaustion, and reinvigorating the anti-cancer response has been central to the development of novel therapies.